GlassScriptPhysician profile
William D Robinson
NPI 1891176111
$4,583.20
in general payments reported to CMS, 2019-2025
34 companies · $873 in 2025
The $873 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.55 · 2021: $589 · 2022: $1,004 · 2023: $878 · 2024: $1,226 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,977.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,977.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $711.20 | 2021-2025 | Vraylar, Linzess, Ubrelvy |
| Pfizer INC. | $592.20 | 2022-2025 | |
| Novo Nordisk INC | $578.69 | 2021-2025 | Wegovy, Ozempic, Saxenda |
| Amgen INC. | $439.32 | 2021-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $436.56 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $401.14 | 2020-2025 | |
| Xeris Pharmaceuticals, INC. | $187.85 | 2021-2023 | Gvoke Hypopen, Keveyis |
| Glaxosmithkline, LLC. | $149.98 | 2021-2024 | Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $140.00 | 2021-2024 | Xarelto |
| Edwards Lifesciences Corporation | $110.70 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.08 | 2021-2025 | Ofev, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $74.00 | 2022-2023 | |
| Boston Scientific Corporation | $72.87 | 2023-2024 | Wavewriter Alpha Prime 16 |
| Daiichi Sankyo INC. | $70.28 | 2021-2024 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $61.59 | 2022-2025 | Camzyos |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $53.29 | 2022 | |
| Abbott Laboratories | $48.84 | 2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $47.59 | 2021-2025 | Hyqvia |
| Lundbeck LLC | $43.15 | 2023-2024 | Vyepti |
| Sanofi-Aventis U.S. LLC | $31.77 | 2022 | |
| Horizon Therapeutics Plc | $30.69 | 2021-2022 | |
| Medtronic, INC. | $27.50 | 2022-2024 | Intellis Adaptivestim |
| Inspire Medical Systems, INC. | $25.36 | 2023 | Inspire |
| Dexcom, INC. | $21.59 | 2021 | |
| Philips North America LLC | $18.67 | 2024 | (Ck7) Extended Holter |
| Esperion Therapeutics, INC. | $16.88 | 2021 | |
| Merck Sharp & Dohme LLC | $15.96 | 2023 | Belsomra |
| Phathom Pharmaceuticals, INC. | $15.34 | 2023 | Voquezna |
| Astellas Pharma US INC | $14.50 | 2024 | Veozah |
| Exact Sciences Corporation | $14.08 | 2025 | Cologuard Collection Kit |
| Azurity Pharmaceuticals, INC. | $13.85 | 2025 | Horizant |
| Kowa Pharmaceuticals America, INC. | $12.21 | 2022 | |
| Idorsia Pharmaceuticals US INC | $11.83 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.